{"disease":{"id":"plaque-psoriasis-psoriatic-arthritis","name":"plaque psoriasis psoriatic arthritis"},"drugs":{"marketed":[{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe plaque psoriasis and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04614831","title":"A Worldwide Survey on the Understanding of Psoriatic Disease Among Patients With Psoriasis and Psoriatic Arthritis","phase":"","overall_status":"COMPLETED","enrollment_count":4978,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06802848","title":"Real-World Study of Xeligekimab for Moderate to Severe Plaque Psoriasis(XP-Real)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Chongqing Genrix Biopharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT03370133","title":"A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":567,"lead_sponsor_name":"UCB Biopharma SRL","has_results":true},{"nct_id":"NCT06382051","title":"Modifying PEST for Psoriatic Arthritis Screening","phase":"NA","overall_status":"RECRUITING","enrollment_count":502,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03410992","title":"A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":435,"lead_sponsor_name":"UCB Biopharma SRL","has_results":true},{"nct_id":"NCT05855967","title":"A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":250,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT05155098","title":"2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis","phase":"","overall_status":"COMPLETED","enrollment_count":127,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06506916","title":"A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"UCB Biopharma SRL","has_results":false},{"nct_id":"NCT06888193","title":"A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"UCB Biopharma SRL","has_results":false}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}